# TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

> **NCT04414046** · PHASE2 · RECRUITING · sponsor: **Johns Hopkins All Children's Hospital** · enrollment: 17 (estimated)

## Conditions studied

- Primary Immune Deficiency Disorders
- Metabolic Disease

## Interventions

- **BIOLOGICAL:** Haploidentical Hematopoietic Cell Transplantation

## Key facts

- **NCT ID:** NCT04414046
- **Lead sponsor:** Johns Hopkins All Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-22
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04414046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04414046, "TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04414046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*